Navigation Links
Nfocus Neuromedical Announces FDA 510(k) Clearance for Next Generation Device to Treat Vascular Lesions
Date:1/11/2011

PALO ALTO, Calif., Jan. 11, 2011 /PRNewswire/ -- Nfocus Neuromedical, Inc., an innovative medical device company with a focus on the next generation treatment for brain aneurysms, today announced that the company received U.S. Food and Drug Administration 510(k) clearance for its Acta™ Vessel Occlusion System (VOS).  The Acta VOS provides physicians with a minimally-invasive alternative to current treatment options for an array of common and potentially serious vascular lesions.

The Acta VOS is designed to occlude (close) targeted veins and arteries with great precision. Vascular occlusion is often used to block blood flow to malformed, weakened or leaking vessels, or to benign or malignant tumors.

"The Acta VOS and the Nfocus technology platform on which it's based address an important and, to this date, insufficiently resolved medical need," said Eric Milledge, chairman and CEO, Nfocus Neuromedical.  "The Acta 510(k) clearance is a tangible demonstration of our company's progress and is the first step toward clearance of the Nfocus platform of braided occluders, which includes the Luna™, our flagship product for treating brain aneurysms."

Vascular occlusions were historically accomplished by surgically closing the targeted blood vessel – a traumatic and expensive procedure. More recently, surgeons began placing small wire coils and other vascular plugs through catheters to stop blood from flowing to the area of concern. However, several coils may be required to occlude a single vessel, and occlusions frequently re-open. Pre-clinical studies demonstrate that the Acta VOS stops blood flow in a vessel more quickly and durably than both coils and a predicate plug device.

The Acta VOS uses a self-expandable, multi-layer oval implant made from Nitinol, a nickel-titanium alloy. Nitinol's properties allow the device to easily compress within a conventional catheter, and then rapidly open to full size once deployed within a vessel.  The Acta VOS is mounted on an elegant delivery system that allows physicians to easily retract and reposition the device.  Once the device is deployed and the desired location is achieved, a single lever detaches the Acta VOS, leaving it behind to occlude blood flow.  

"The FDA has rigorous requirements for embolization devices such as the Acta VOS," said Robert O'Holla, vice president of regulatory affairs, Nfocus Neuromedical.  "This 510(k) clearance provides strong validation for both our technology platform and development approach."

About Nfocus Neuromedical, Inc.

Nfocus is developing the next generation treatment for brain aneurysms. The company's innovative LUNA™ product is a single-deployment, easy-to-use embolization device designed to be a direct replacement to detachable coils. Nfocus is backed by three major U.S. and OUS-based venture funds: DFJ ePlanet Capital, Technology Partners, and InCube Ventures. Other investors include Raffles Capital and Endeavor Vision. More information can be found at www.nfocusneuro.com.  


'/>"/>
SOURCE Nfocus Neuromedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dehaier Medical Announces Participation in Arab Health 2011
2. CareFusion Announces Sale of OnSite Services Instrument Management and Repair Business
3. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
4. Stereotaxis Announces CE Mark and First Human Case for Vdrive™
5. AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device
6. STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million
7. Mithridion, Inc. Announces New Funding and Outlines Strategy for Central Nervous System Drug Development
8. Nalco Announces Price Increase
9. Vasomedical Announces Launch of Its Online Company Store
10. Mindray Medical Announces Preliminary 2010 Operating Results
11. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
(Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
Breaking Medicine Technology:
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
Breaking Medicine News(10 mins):